Patent exhaustion
An authorized sale of a patented article exhausts the patentee's rights in that article. The buyer takes the right to use, resell, or import the article free of any further patent infringement claim by the seller, and post-sale restrictions cannot be enforced through the patent laws — though they may sometimes be enforced as contracts. The doctrine extends to authorized international sales and reaches sales of components that substantially embody patented methods.
The rule
An authorized sale of a patented item terminates the patentee's right to enforce the patent against further use, resale, or importation of that item. Impression Products, Inc. v. Lexmark International, Inc., 581 U.S. 360, 365 (2017). Two propositions follow.
First, post-sale restrictions imposed at the time of sale — single-use-only conditions, geographic restrictions, no-resale clauses — cannot be enforced through patent infringement litigation, though they may sometimes be enforced as ordinary contractual obligations. Id. at 374. The patentee's rights are extinguished at the point of sale.
Second, the rule applies to authorized international sales. Id. at 380. A patented article sold abroad with the patentee's authorization may be imported and resold in the United States free of patent infringement liability. The Court rejected the Federal Circuit's contrary "international exhaustion" rule and aligned patent exhaustion with copyright's "first sale" doctrine in Kirtsaeng v. John Wiley & Sons, Inc., 568 U.S. 519 (2013).
For method patents, the authorized sale of a component that substantially embodies the method exhausts the patent. Quanta Computer, Inc. v. LG Electronics, Inc., 553 U.S. 617, 638 (2008). For self-replicating products, exhaustion does not extend to making new copies; planting and growing seeds purchased from an authorized seller, for example, is "making" rather than "using." Bowman v. Monsanto Co., 569 U.S. 278, 287 (2013).
Statutory and constitutional source
Patent exhaustion is a common-law doctrine that long predates the modern Patent Act. The Supreme Court traced its origins to Bloomer v. McQuewan, 55 U.S. (14 How.) 539 (1852), and emphasized in Impression Products that the doctrine reflects the common law's hostility to restraints on alienation of personal property. 581 U.S. at 366. As Justice Roberts put it, when a patentee sells an item, the item "becomes the private, individual property of the purchaser, with the rights and benefits that ownership of property confers." Id. at 367.
The doctrine operates as a limit on the patentee's exclusive rights under 35 U.S.C. § 271(a) ("makes, uses, offers to sell, sells, or imports"). After an authorized sale, the buyer's use, resale, and importation of the item are no longer "without authority" within the meaning of § 271(a). The Court has been clear that exhaustion is a categorical rule, not a default term that can be varied by post-sale notice or condition. 581 U.S. at 376.
The doctrine has constitutional resonance with the Patent and Copyright Clause's "limited Times" requirement, U.S. Const. art. I, § 8, cl. 8, and the longstanding common-law antipathy toward post-sale restraints, but the Court has not grounded exhaustion in any specific constitutional provision.
The framework the courts apply
Authorized sale
Exhaustion requires an authorized sale. The seller must hold the patent rights or be authorized to sell by the patentee through a license. The leading question is whether the sale was within the scope of the seller's authority.
In Quanta, LGE licensed Intel to make and sell microprocessors and chipsets that practiced LGE's method patents, with a notice provision purporting to require Intel to inform its customers that the license did not extend to combinations with non-Intel components. The Court held that the license authorized Intel's sales without restriction, and that the post-sale "notice" did not impose any limit on exhaustion. 553 U.S. at 636–37. Once Intel sold the chips, LGE's patent rights were exhausted as to those chips.
By contrast, where a license restricts the licensee's authority to make sales — for example, by limiting sales to a particular field of use or to a particular geographic region — sales outside the scope of the license are unauthorized and do not exhaust the patent. General Talking Pictures Corp. v. Western Electric Co., 304 U.S. 175 (1938).
Substantial embodiment for method patents
Method patents present a special question because methods cannot be "sold" in the same way as products. Quanta held that the authorized sale of a product that substantially embodies a method patent — that is, the product has no reasonable non-infringing use and has the characteristics that make the patented method function — exhausts the patent. 553 U.S. at 633–34. The substantial-embodiment test prevents patentees from defeating exhaustion by asserting method claims after authorized sales of the products that practice them.
International sales
Before Impression Products, the Federal Circuit held that authorized foreign sales did not exhaust U.S. patent rights. Jazz Photo Corp. v. International Trade Commission, 264 F.3d 1094 (Fed. Cir. 2001). The Supreme Court reversed that rule. 581 U.S. at 380. An authorized sale abroad — even at a price reduced for the foreign market — exhausts the U.S. patent, and the article may be imported and resold in the United States.
Self-replicating products
Exhaustion does not authorize "making" new copies of the patented invention. Bowman held that a farmer who purchased commodity grain from an authorized Monsanto licensee could not plant the grain to grow new generations of glyphosate-resistant soybeans, because growing new plants is "making" rather than "using." 569 U.S. at 287. The first generation purchased from the elevator was within the buyer's exhaustion rights; subsequent generations, grown from those seeds, were not.
The Court was careful to limit its holding. It declined to "address every situation involving a self-replicating product," noting in particular that some self-replication might be "necessary but incidental" to the article's authorized use — for example, software that replicates itself in operating-system memory. Id. at 289.
Post-sale restrictions
The Federal Circuit in Mallinckrodt, Inc. v. Medipart, Inc., 976 F.2d 700 (Fed. Cir. 1992), had permitted patentees to enforce post-sale restrictions through patent infringement claims, provided the restrictions were within the patent's scope. Impression Products overruled this approach. 581 U.S. at 374. Post-sale restrictions are not enforceable through patent law; the patentee may sue in contract if the restriction was negotiated and otherwise lawful, but a downstream purchaser without privity to that contract is generally beyond reach.
Burden and proof
Patent exhaustion is an affirmative defense to infringement. The accused infringer bears the burden of production: identifying an authorized sale of the accused article. The patentee may rebut by showing that the asserted "sale" was outside the seller's authority — for example, that the sale violated a field-of-use restriction in the seller's license.
The standard of proof for the affirmative defense is preponderance of the evidence. This is lower than the clear-and-convincing standard applicable to anticipation, obviousness, and other invalidity defenses, reflecting that exhaustion goes to the patentee's right to assert infringement rather than to the patent's validity.
Exhaustion is typically a question of law applied to factual findings about the chain of title and the scope of any license. Where the underlying facts are undisputed, the question is reviewed de novo on appeal; where the facts are disputed, the underlying findings are reviewed for clear error.
Interaction with related doctrines
Patent exhaustion is one of several doctrines that limit the patentee's ability to extract value beyond a single authorized sale. The doctrine of "patent misuse" — a defense rooted in equity — bars enforcement of a patent that has been used to extend the patent's scope through tying arrangements or other anticompetitive conduct. Morton Salt Co. v. G.S. Suppiger Co., 314 U.S. 488 (1942). Although exhaustion and misuse can both arise from post-sale conditions, they are distinct: exhaustion focuses on whether the patentee retains rights to assert against a particular item, while misuse asks whether the patentee has overreached such that the patent should be unenforceable until the misuse is purged.
Exhaustion sits alongside the "implied license" doctrine: where an authorized sale comes with no express license but the buyer reasonably anticipates a particular use, an implied license may attach. Exhaustion is broader and more categorical, but courts sometimes resolve disputes on either theory.
The doctrine bears on remedies analysis. Where a defendant's products were lawfully obtained downstream from authorized first sales, exhaustion can defeat infringement entirely, eliminating any claim for reasonable royalty or lost profits. Where exhaustion does not defeat liability — for example, in self-replicating-product cases like Bowman — damages turn on the unauthorized "making" rather than the authorized purchase.
Exhaustion can also affect permanent injunction analysis under eBay v. MercExchange: where a substantial portion of the accused conduct occurs after an authorized sale, the equities under the eBay four-factor test may shift.
The doctrine intersects with ITC Section 337 proceedings governing imports. After Impression Products, articles authorized for sale abroad cannot be excluded from importation on the basis of patent infringement, eliminating one route by which patentees had previously sought to enforce regional pricing.
Practical notes
For patentees, the practical consequence of Impression Products is that contract — not patent — is the principal vehicle for downstream control. Patent owners that wish to limit post-sale conduct must do so through enforceable contracts with their direct purchasers, and contractual privity ordinarily limits the reach to those direct purchasers. Conditions printed on packaging or product labels — the form at issue in Impression Products — generally do not bind downstream purchasers in patent or contract.
Licensing structures should be reviewed in light of Quanta. A license that authorizes sales without restriction will exhaust the patent as to those sales, even if the patentee includes a contractual notice attempting to require downstream notice. To preserve patent rights against downstream conduct, the license itself must restrict the licensee's authority — for example, to particular fields of use, particular geographic regions, or particular customers — and the licensee's sales must conform to that restriction.
For international pricing, regional differentiation is no longer protected by patent law within the United States. Patentees that price below the U.S. market in foreign jurisdictions face the risk of arbitrage by importers (the "gray market"). Strategies include foreign sales subject to enforceable contractual restrictions on resale into the U.S., supply-side controls (limited authorized distributors), and reliance on the trademark and customs regime where applicable.
For pharmaceutical and biotechnology patentees, Bowman's self-replicating-products carve-out remains important. Seed companies, biological-reagent makers, and producers of any technology where authorized first generations can produce subsequent generations should rely on Bowman to assert infringement against unauthorized propagation, while remembering the Court's narrow framing.
For accused infringers and downstream purchasers, the chain-of-title inquiry is the first line of defense. Records of supplier authorization, supplier license terms, and the geographic and field-of-use scope of those licenses determine whether exhaustion applies. Where products move through multiple distributors, defendants commonly need supplier discovery to establish exhaustion.
Open questions
The interaction between Impression Products and contractual post-sale restrictions remains the subject of active development. The Court left open the possibility that single-use, no-resale, and similar restrictions might be enforceable in contract against direct purchasers, but did not address what happens when a downstream purchaser receives notice of the restriction. Lower courts continue to develop the doctrine.
The "substantial embodiment" test from Quanta has produced uneven application. The Federal Circuit has applied it both narrowly and broadly in subsequent cases, and the boundaries — particularly for software products that incorporate patented methods — remain unclear.
The reach of Bowman's self-replication exception is also unsettled. Software, biological reagents, and machine-learning models that replicate themselves as part of authorized use raise questions the Court explicitly did not resolve. The Federal Circuit has not yet addressed self-replicating digital technologies in a definitive manner.
Finally, the relationship between Impression Products and the antitrust laws — particularly with respect to international price discrimination — has not been comprehensively examined. Patentees that attempt to enforce post-sale restrictions through aggressive contractual or tying arrangements may face misuse or antitrust challenges, but the doctrinal contours remain in flux.
See also
- Direct infringementExhaustion is an affirmative defense to §271(a) direct-infringement claims.
- Indirect infringementAuthorized first sale of a component can also exhaust induced and contributory infringement theories.
- Permanent injunctionsExhaustion can affect the equitable balance under eBay's four-factor test.
- Reasonable royaltyExhaustion can eliminate damages claims against authorized downstream conduct.
- Lost profitsSame — authorized sales preclude lost-profit claims as to those sales.
- eBay v. MercExchangeGoverns injunction analysis after exhaustion-limited liability.
- ITC Section 337Cannot exclude articles whose foreign sales were authorized after Impression Products.
- StandingExhaustion can affect a patentee's ability to sue downstream purchasers.
- GlossaryDefinitions of "authorized sale," "substantial embodiment," and related terms.
- Title 35 referenceStatutory text of §271 and related provisions.
Last reviewed: 2026